I-MAB (IMAB) has released an update.
I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung cancer, with strong early data boosting confidence in its cancer treatment pipeline. With a cash runway extending into 2027 and strategic deals like the Sanofi partnership, I-Mab is poised for significant growth in the coming years.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
